DUBLIN--(BUSINESS WIRE)--Sep 14, 2018--The "Moderate Psoriasis - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report offers a comprehensive insight of the pipeline (under development) therapeutics scenario and growth prospects across Moderate Psoriasis development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Scope

The report provides a snapshot of the pipeline development for Moderate Psoriasis The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for Moderate Psoriasis The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Moderate Psoriasis The report also covers the dormant and discontinued pipeline projects related to Moderate Psoriasis

Key Topics Covered

1. Report Introduction

2. Moderate Psoriasis Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Moderate Psoriasis

4. Comparative Analysis

5. Products in Clinical Stage

5.1 Drug Name : Company Name

Product Description Research and Development Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

6.1 Drug Name : Company Name

Product Description Research and Development Product Development Activities

7. Therapeutic Assessment

Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type

8. Inactive Products

8.1 Drug Name : Company Name

Product Description Research and Development Product Development Activities

Companies Featured

AbGenomics International ADC Therapeutics Sarl Almirall AstraZeneca Plc Avexxin AS Boehringer Ingelheim GmbH Celgene Corporation Convoy Therapeutics Crescendo Biologics Limited Delenex Therapeutics AG Eli Lilly and Company

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/fdqvtd/moderate?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180914005282/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs,Psoriasis Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/14/2018 08:58 AM/DISC: 09/14/2018 08:58 AM

http://www.businesswire.com/news/home/20180914005282/en